Cipher Pharmaceuticals (PHE) AI Stock Analysis
Cipher Pharmaceuticals
(Frankfurt:PHE)
No summary available
Cipher Pharmaceuticals (PHE) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 236.36M
- Dividend Yield
- ―
- Average Volume (3M)
- 500
- Price to Earnings (P/E)
- 8.3
- Beta (1Y)
- 0.12
- Revenue Growth
- -2.75%
- EPS Growth
- 127.87%
- Country
- Germany
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Cipher Pharmaceuticals Business Overview & Revenue Model
Company Description
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), for...
Cipher Pharmaceuticals Earnings Call Summary
The call conveyed a cautiously positive outlook: while the U.S. business (Natroba) experienced clear top-line pressure—driving a 10% decline in quarter revenue and a 19% decline in Natroba sales versus prior year—the company offset those headwinds with strong margin performance, SG&A reductions, cash generation, year-to-date EBITDA growth (+6% YTD), and concrete commercial and reimbursement progress for Epuris (14% revenue growth, expanded pCPA LOI and 47.1% market share). Management laid out actionable mitigation plans for U.S. channel diversification (DTC, retail, delivery), maintained an opportunistic M&A/in-licensing posture, and preserved liquidity and financing optionality. Overall, positives (sustained high margins, Epuris momentum, cost efficiencies, solid cash and financing capacity) meaningfully outweigh the operational revenue setbacks in the quarter.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that they expect near-term improvement in U.S. performance for Natroba as they scale new commercial channels (direct-to-patient launched earlier this year, direct mail/same-day delivery and national retail placement such as Walmart) while continuing to pursue in‑licensing, out‑licensing and acquisitions; key metrics discussed include Q2 net revenue of $12.1M (Q2 Natroba $6.3M vs $7.8M prior year; Epuris $4.1M, +$0.5M or +14%), six‑month revenue $24.6M, Q2 gross margin 80% (YTD 81%), Q2 adjusted EBITDA $6.8M (‑10% YoY) at a 57% margin, YTD adjusted EBITDA $14.6M (+6% YoY) at a 59% margin, Q2 net income $4.0M ($0.15/sh) and YTD net income $10.2M ($0.39/sh), Epuris sales volume +8% in Q2 and market share up 1.3 pts to 47.1% as of June 30, 2026, cash $9.1M, operating cash flow $7.6M YTD, debt‑free with $90M of potential financing capacity (a $65M revolver plus $25M accordion), and an expected timeline of 30–60 days to finalize expanded public drug‑plan listings for Epuris that management said should meaningfully expand the product’s addressable market and drive future market‑share growth.
Cipher Pharmaceuticals Peers Comparison
Overall Rating
TSE:RX78Outperform
TSE:MDP63Neutral
TSE:GUD59Neutral
TSE:HLS58Neutral
TSE:CRDL42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:RX | 78Outperform | CAD 193.27M | 19.38 | 22.92% | 1.26% | 40.91% | 19.88% |
| TSE:MDP | 63Neutral | CAD 154.93M | -45.35 | -4.69% | ― | -3.16% | -345.50% |
| TSE:GUD | 59Neutral | CAD 1.11B | 76.95 | 1.91% | ― | 42.32% | 4332.35% |
| TSE:HLS | 58Neutral | CAD 139.52M | -12.23 | -14.43% | ― | -1.18% | 42.93% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:CRDL | 42Neutral | CAD 195.47M | -4.27 | -180.13% | ― | ― | 29.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:PHE | Cipher Pharmaceuticals Inc | 8.10 | -0.85 | -9.50% | |
| TSE:GUD | Knight Therapeutics | 11.32 | 5.52 | 95.17% | |
| TSE:MDP | Medexus Pharmaceuticals | 4.84 | 2.15 | 79.93% | |
| TSE:RX | Biosyent Inc | 17.05 | 6.22 | 57.37% | |
| TSE:HLS | Hls Therapeutics | 4.47 | -0.95 | -17.53% | |
| TSE:CRDL | Cardiol Therapeutics Inc. | 1.47 | -0.01 | -0.68% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.